S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MRNS Marinus Pharmaceuticals Inc

0.3279

0.0061 (1.90%)

28 Nov 2024 - Closed

Delayed by 15 minutes

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

null

Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Marinus Pharmaceuticals Charts.

Marinus Pharmaceuticals (NASDAQ:MRNS)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Marinus Pharmaceuticals Charts.

Marinus Pharmaceuticals Inc News

Form 8-K - Current report
Saturday 16 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Wednesday 13 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Wednesday 13 November 2024 (2 weeks ago) • Business Wire

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Saturday 2 November 2024 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 24 October 2024 (1 month ago) • Edgar (US Regulatory)

Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
Thursday 24 October 2024 (1 month ago) • Business Wire

Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
Thursday 17 October 2024 (1 month ago) • Business Wire

More Marinus Pharmaceuticals Inc News Articles

Woodside Petroleum

Westpac Banking

Australian SE All Ordina...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions